Abstract
Background
Methods
Results
Conclusion
Figures and Tables
Fig. 1
Randomization scheme and patient disposition. IBN+, the group which received a once-monthly pill containing 150 mg ibandronate and 24,000 IU cholecalciferol; IBN, the group which received a once-monthly pill containing 150 mg ibandronate.
![enm-30-272-g001](/upload/SynapseData/ArticleImage/2008enm/enm-30-272-g001.jpg)
Fig. 2
Changes in mean serum 25(OH)D levels over the 16-week treatment period. IBN+, the group which received a once-monthly pill containing 150 mg ibandronate and 24,000 IU cholecalciferol; IBN, the group which received a once-monthly pill containing 150 mg ibandronate; 25(OH)D, 25-hydroxyvitamin D. aP<0.001.
![enm-30-272-g002](/upload/SynapseData/ArticleImage/2008enm/enm-30-272-g002.jpg)
Fig. 3
Changes in the distribution of patients according to 25-hydroxyvitamin D (25[OH]D) levels after the 16-week treatment period. IBN+, the group which received a once-monthly pill containing 150 mg ibandronate and 24,000 IU cholecalciferol; IBN, the group which received a once-monthly pill containing 150 mg ibandronate treatment period, grouped by baseline 25(OH)D levels.
![enm-30-272-g003](/upload/SynapseData/ArticleImage/2008enm/enm-30-272-g003.jpg)
Table 1
Baseline Characteristics of the Participants
![enm-30-272-i001](/upload/SynapseData/ArticleImage/2008enm/enm-30-272-i001.jpg)
Values are expressed as mean±SD or number (%).
IBN+, the group which received a once-monthly pill containing 150 mg ibandronate and 24,000 IU cholecalciferol; IBN, the group which received a once-monthly pill containing 150 mg ibandronate; NS, not significant; BMD, bone mineral density; 25(OH)D, 25-hydroxyvitamin D; PTH, parathyroid hormone; BSAP, bone-specific alkaline phosphatase; CTX, C-telopeptide of type 1 collagen.
Table 2
Changes in the Serum Levels of 25(OH)D, Bone Turnover Markers, Parathyroid Hormone, Calcium, and Phosphorus after the 16-Week Treatment Course
![enm-30-272-i002](/upload/SynapseData/ArticleImage/2008enm/enm-30-272-i002.jpg)
Values are expressed as mean±SD.
25(OH)D, 25-hydroxyvitamin D; IBN+, the group which received a once-monthly pill containing 150 mg ibandronate and 24,000 IU cholecalciferol; IBN, the group which received a once-monthly pill containing 150 mg ibandronate; NS, not significant; CTX, C-telopeptide of type 1 collagen; BSAP, bone-specific alkaline phosphatase; PTH, parathyroid hormone.
aWilcoxon's rank sum test; bWilcoxon's signed rank test; ct test; dPaired t test.
Table 3
Changes in the Mean Serum Levels of 25(OH)D and CTX after the 16-Week Treatment Course, Grouped by Baseline 25(OH)D Levels
![enm-30-272-i003](/upload/SynapseData/ArticleImage/2008enm/enm-30-272-i003.jpg)
Values are expressed as mean±SD.
25(OH)D, 25-hydroxyvitamin D; CTX, C-telopeptide of type 1 collagen; IBN+, the group which received a once-monthly pill containing 150 mg ibandronate and 24,000 IU cholecalciferol; IBN, the group which received a once-monthly pill containing 150 mg ibandronate; NS, not significant.
at test; bWilcoxon's rank sum test; cPaired t test; dWilcoxon's signed rank test.